2024

High efficacy of the F-ATP synthase inhibitor TBAJ-5307 against non-tuberculous mycobacteria in vitro and in vivo.
P. Ragunathan, P. Sae-Lao, C. Hamela, M. Alcaraz, A. Krah, W. Han Poh, C. Jia Ern Pee, A. Yick Hou Lim, S. A. Rice, K. Pethe, P. John Bond, T. Dick, L. Kremer*, R. W. Bates*, and G. Grüber*. 2024. J. Biol. Chem. 300:105618. *Co-last corresponding authors.

2023

In vitro and in vivo efficacy of NITD-916 against Mycobacterium fortuitum.
F. Roquet-Banères*, M. Alcaraz*, C. Hamela*, J. Abendroth, T. E. Edwards, and L. Kremer. 2023. Antimicrob. Agents Chemother. e01607-22. *Co-first authors

2022

Tricyclic SpiroLactams kill mycobacteria in vitro and in vivo by inhibiting type II NADH dehydrogenases.
S. Dam*, S. Tangara*, C. Hamela*, T. Hattabi, L. Faïon, P. Carre, R. Antoine, A. Herledan, F. Leroux, C. Piveteau, M. Eveque, M. Flipo, B. Deprez, L. Kremer, N. Willand, B. Villemagne, and R.C. Hartkoorn. 2022. J. Med. Chem. 65: 16651-16664. *Co-first authors

Glycopeptidolipid glycosylation controls surface properties and pathogenicity in Mycobacterium abscessus.
W. Daher, L.-D. Leclercq, M. D. Johansen, C. Hamela, J. Karam, X. Trivelli, J. Nigou, Y. Guérardel, and L. Kremer. 2022. Cell Chem. Biol. 29: 1-15.

2021

Efficacy of epetraborole against Mycobacterium abscessus is increased with norvaline
J. R. Sullivan, A. Lupien, E. Kalthoff, C. Hamela, L. Taylor, K. A. Munro, T. M. Schmeing, L. Kremer, and M. A. Behr. 2021. PLOS Pathog. 17: e1009965.

Mycobacteriophage-antibiotic therapy promotes enhanced clearance of drug-resistant Mycobacterium abscessus
D. Johansen, M. Alcaraz, R.M. Dedrick, F. Roquet-Banères, C. Hamela, G. F. Hatfull, and L. Kremer. 2021. Dis. Model. Mech. 14: dmm049159.

2020

Functional Characterization of the N-Acetylmuramyl-l-Alanine Amidase, Ami1, from Mycobacterium abscessus
Küssau T, Van Wyk N, Johansen MD, Alsarraf HMAB, Neyret A, Hamela C, Sørensen KK, Thygesen MB, Beauvineau C, Kremer L, Blaise M.Cells. 2020 Nov 4;9(11):2410. doi: 10.3390/cells9112410.